| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 04/03/2002 | EP1192253A1 Icbp90 polypeptide and its fragments and polynucleotides coding for said polypeptides and applications for diagnosing and treating cancer |
| 04/03/2002 | EP1192250A2 Human rna metabolism proteins (rmep) |
| 04/03/2002 | EP1192249A1 47 human secreted proteins |
| 04/03/2002 | EP1192248A1 Antisense modulation of ship-2 expression |
| 04/03/2002 | EP1192247A1 Sphingosine kinase enzyme |
| 04/03/2002 | EP1192181A1 Methods for modulating angiogenesis by using the anti-angiogenic angiotensin-7 and polynucleotides encoding therefor |
| 04/03/2002 | EP1192179A2 Compound derived from an offset orf of the ice gene |
| 04/03/2002 | EP1192176A1 49 human secreted proteins |
| 04/03/2002 | EP1192174A2 Antagonists of bmp and tgf beta signalling pathways |
| 04/03/2002 | EP1192171A1 48 human secreted proteins |
| 04/03/2002 | EP1191948A2 High dose radionuclide complexes for bone marrow suppression |
| 04/03/2002 | EP1191945A1 Methods and compositions for control of bone formation via modulation of leptin activity |
| 04/03/2002 | EP1191942A2 Treatment of endometriosis with antileukoprotease |
| 04/03/2002 | EP1191941A1 A method for the prophylaxis and/or treatment of medical disorders |
| 04/03/2002 | EP1191940A1 Tumor necrosis factor receptor 5 |
| 04/03/2002 | EP0856051B1 Novel 3' terminal sequence of hepatitis c virus genome and diagnostic and therapeutic uses thereof |
| 04/03/2002 | EP0775199B1 Superoxide dismutase-4 |
| 04/03/2002 | EP0736002B1 Compound capable of introducing at least one molecule into a cell |
| 04/03/2002 | EP0621786B1 Induced tolerance to xenografts |
| 04/03/2002 | CN1343259A Identification of genes having role in presentation of diabetic nephropathy |
| 04/03/2002 | CN1343118A Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes |
| 04/03/2002 | CN1342673A Polypeptide-transcription factor XAP-2 protein 49.72 and polynucleotide for coding it |
| 04/03/2002 | CN1342493A IL6/IL2 fusion protein method for inducing differentiation of chronic granulocytic leukemia |
| 04/03/2002 | CN1082043C Novel cationic lipids and the use thereof |
| 04/02/2002 | US6365715 Human cardiac/brain tolloid-like protein |
| 04/02/2002 | US6365712 Isolated soluble cd antigen; diagnosis and treatment of related disorders |
| 04/02/2002 | US6365577 Administering to the subject, in a suitable pharmaceutical carrier, a pharmaceutically effective amount of an antisense agent which is morpholino oligonucleotide for inhibiting expression of p53 |
| 04/02/2002 | US6365576 Topically administering to the cornea a dna sequence that encodes interferon .alpha.1, and a promoter operatively linked to the dna sequence; wherein promoter induces constitutive expression of dna sequence |
| 04/02/2002 | US6365575 Gene delivery and expression in areas inaccessible to direct protein delivery |
| 04/02/2002 | US6365402 Growth differentiation factor-9 |
| 04/02/2002 | US6365394 Cell lines and constructs useful in production of E1-deleted adenoviruses in absence of replication competent adenovirus |
| 04/02/2002 | US6365393 Recombinant virus with an insertion in the hind iii fragment i region; immunomodulators |
| 04/02/2002 | US6365389 Human protein kinase H2LAU20 |
| 04/02/2002 | US6365374 2′-deoxy-2′-alkylnucleotide containing nucleic acid |
| 04/02/2002 | US6365370 Dna which codes for 5-hydroxytryptamine 3-c protein of defined amino acid sequence; antiinflammatory agents; treatment of huntington's disease, alzheimer's disease and others |
| 04/02/2002 | US6365369 Polynucleotide which encodes a specific amino acid sequence; diagnosis and therapy of urogenital disorders |
| 04/02/2002 | US6365365 Method of determining whether an agent modulates glycosyl sulfotransferase-3 |
| 04/02/2002 | US6365354 Antisense modulation of lysophospholipase I expression |
| 04/02/2002 | US6365351 Non-invasive method for detecting target RNA |
| 04/02/2002 | US6365159 Spo-rel |
| 04/02/2002 | US6365151 Transfection; genetic engineering |
| 04/02/2002 | US6365150 Mixture of vectors; genetic engineering; transfection |
| 04/02/2002 | US6364893 Stent lining |
| 03/29/2002 | CA2340303A1 Rna-binding protein |
| 03/28/2002 | WO2002024957A1 Methods and compositions for modulating angiogenesis |
| 03/28/2002 | WO2002024950A2 Methods and means of rna analysis |
| 03/28/2002 | WO2002024934A1 Chimeric vectors and their use for heterologous genes transfer |
| 03/28/2002 | WO2002024933A2 Viral vectors having tissue tropism for t-lymphocytes, b- and mast cells |
| 03/28/2002 | WO2002024932A2 Expression vectors containing hybrid ubiquitin promoters |
| 03/28/2002 | WO2002024931A1 Expression system for functional nucleic acids |
| 03/28/2002 | WO2002024930A2 Artificial ubiquitous chromatin opening elements (ucoe) |
| 03/28/2002 | WO2002024924A2 Protein phosphatases |
| 03/28/2002 | WO2002024916A1 Complex |
| 03/28/2002 | WO2002024909A2 Receptor nucleic acids and polypeptides |
| 03/28/2002 | WO2002024908A1 Novel tissue-specific secretory polypeptide and dna thereof |
| 03/28/2002 | WO2002024906A1 Induction of exon skipping in eukaryotic cells |
| 03/28/2002 | WO2002024899A2 Improved system for regulation of transgene expression |
| 03/28/2002 | WO2002024897A2 Conditionally replicating viral vectors and their use |
| 03/28/2002 | WO2002024891A2 B7-like molecules and uses thereof |
| 03/28/2002 | WO2002024747A2 Polymorphisms in human genes of cardiovascular regulators and their use in diagnostic and therapeutic applications |
| 03/28/2002 | WO2002024735A2 Peptide inhibitors of hiv entry |
| 03/28/2002 | WO2002024733A2 Human polynucleotides and polypeptides encoded thereby |
| 03/28/2002 | WO2002024730A2 Transduction of dendritic cells using adenoviral vectors |
| 03/28/2002 | WO2002024727A2 New inhibitors of iapp fibril formation and uses thereof |
| 03/28/2002 | WO2002024721A1 21 human secreted proteins |
| 03/28/2002 | WO2002024720A1 Antisense modulation of caspase 2 expression |
| 03/28/2002 | WO2002024718A1 Compositions and methods relating to prostate specific genes and proteins |
| 03/28/2002 | WO2002024717A1 Antisense modulation of flip-c expression |
| 03/28/2002 | WO2002024640A2 Recombinant adenovirus vectors that are replication-competent in tert-expressing cells |
| 03/28/2002 | WO2002024234A2 Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
| 03/28/2002 | WO2002024233A2 Control of nk cell function and survival by modulation of ship activity |
| 03/28/2002 | WO2002024232A2 Pei: dna vector formulations for in vitro and in vivo gene delivery |
| 03/28/2002 | WO2002024231A1 Use of a nucleic acid/pei complex |
| 03/28/2002 | WO2002024225A1 Use of immidazoquinolinamines as adjuvants in dna vaccination |
| 03/28/2002 | WO2002024214A2 Use of glp -2 in combination with another therapeutic agent in bone-related and nutrition-related disorders |
| 03/28/2002 | WO2002024148A2 Method or treatment of tumors using transforming growth factor-alpha |
| 03/28/2002 | WO2001098333A3 Modification of hepatitis b core antigen |
| 03/28/2002 | WO2001092550A3 Methods and compositions for efficient gene transfer using transcomplementary vectors |
| 03/28/2002 | WO2001091725A3 Biologically useful polyphosphates |
| 03/28/2002 | WO2001085781A3 Repair of nerve damage |
| 03/28/2002 | WO2001085762B1 Cancer diagnosis and assays for screening anti-cancer agents |
| 03/28/2002 | WO2001083692A3 Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids |
| 03/28/2002 | WO2001081570A3 Heteromultimeric ion channel receptor and uses thereof |
| 03/28/2002 | WO2001079471A3 Self-extinguishing recombinases, nucleic acids encoding them and methods of using the same |
| 03/28/2002 | WO2001079249A3 Peptide nucleic acid derivatives with a negative charge, agents and methods for producing them |
| 03/28/2002 | WO2001074859A3 A gene differentially expressed in breast and bladder cancer and encoded polypeptides |
| 03/28/2002 | WO2001066596A3 Human fgf-23 gene and gene expression products |
| 03/28/2002 | WO2001066107A3 Treatment of diseases associated with cytokine production with inhibitors of the tec family of protein tyrosine kinases |
| 03/28/2002 | WO2001062791A3 Control of tgf (beta) signaling by km23 superfamily members |
| 03/28/2002 | WO2001057194A3 Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon |
| 03/28/2002 | WO2001057182A3 Nucleic acids, proteins, and antibodies |
| 03/28/2002 | WO2001055330A3 Recombinant rhabdoviruses as live-viral vaccines for immunodeficiency viruses |
| 03/28/2002 | WO2001051606A3 Cell line for preparing and producing ovine adenovirus vectors |
| 03/28/2002 | WO2001038552A3 Excipient system that contains coating substances with enzymatically removable side-groups |
| 03/28/2002 | WO2001038486A3 Kunitz-type protease inhibitor polynucleotides, polypeptides, and antibodies |
| 03/28/2002 | WO2001032885A3 Human lipase |
| 03/28/2002 | WO2001009183A3 Polymorphisms in the human mdr-1 gene and applications thereof |
| 03/28/2002 | WO2000063241A9 Methods and compositions for modulating an immune response |
| 03/28/2002 | WO2000060051A3 Arpe-19 as a platform cell line for encapsulated cell-based delivery |
| 03/28/2002 | WO2000047231A9 Novel antisense inhibition of rad51 |